{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T03:38:27Z","timestamp":1782185907941,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-96103-6","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T23:02:52Z","timestamp":1743807772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of dipeptidyl peptidase-4 inhibitor-associated gastrointestinal symptoms using the prescription claims database"],"prefix":"10.1038","volume":"15","author":[{"given":"Ayana","family":"Funabashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoru","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Tsukioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuko","family":"Onda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"key":"96103_CR1","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s41574-020-0399-8","volume":"16","author":"CF Deacon","year":"2020","unstructured":"Deacon, C. F. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat. Rev. Endocrinol. 16, 642\u2013653 (2020).","journal-title":"Nat. Rev. Endocrinol."},{"key":"96103_CR2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41598-022-27301-9","volume":"13","author":"M Nagao","year":"2023","unstructured":"Nagao, M. et al. Efficacy and safety of sitagliptin treatment in older adults with moderately controlled type 2 diabetes: the stream study. Sci. Rep. 13, 134 (2023).","journal-title":"Sci. Rep."},{"key":"96103_CR3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2337\/cd22-as01","volume":"40","author":"American Diabetes Association","year":"2022","unstructured":"American Diabetes Association. Standards of medical care in Diabetes-2022 abridged for primary care providers. Clin. Diabetes. 40, 10\u201338 (2022).","journal-title":"Clin. Diabetes"},{"key":"96103_CR4","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s00125-012-2827-3","volume":"56","author":"YG Kim","year":"2013","unstructured":"Kim, Y. G. et al. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia 56, 696\u2013708 (2013).","journal-title":"Diabetologia"},{"key":"96103_CR5","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/jdi.13636","volume":"13","author":"R Bouchi","year":"2022","unstructured":"Bouchi, R. et al. Retrospective nationwide study on the trends in first-line antidiabetic medication for patients with type 2 diabetes in Japan. J. Diabetes Investig. 13, 280\u2013291 (2022).","journal-title":"J. Diabetes Investig"},{"key":"96103_CR6","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","volume":"132","author":"LL Baggio","year":"2007","unstructured":"Baggio, L. L. & Drucker, D. J. Biology of incretins: GLP-1 and GIP. Gastroenterology 132, 2131\u20132157 (2007).","journal-title":"Gastroenterology"},{"key":"96103_CR7","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1210\/jc.2008-1296","volume":"94","author":"R Abu-Hamdah","year":"2009","unstructured":"Abu-Hamdah, R. et al. Clinical review: the extrapancreatic effects of glucagon-like peptide-1 and related peptides. J. Clin. Endocrinol. Metab. 94, 1843\u20131852 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"96103_CR8","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/pds.3586","volume":"23","author":"X Liu","year":"2014","unstructured":"Liu, X. et al. The long-term efficacy and safety of DPP-IV inhibitors monotherapy and in combination with Metformin in 18,980 patients with type-2 diabetes mellitus\u2013a meta-analysis. Pharmacoepidemiol Drug Saf. 23, 687\u2013698 (2014).","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"96103_CR9","doi-asserted-by":"crossref","first-page":"e30072","DOI":"10.1097\/MD.0000000000030072","volume":"101","author":"YW Wang","year":"2022","unstructured":"Wang, Y. W., Lin, J. H. & Yang, C. S. Meta-analysis of the association between new hypoglycemic agents and digestive diseases. Medicine 101, e30072 (2022).","journal-title":"Medicine"},{"key":"96103_CR10","unstructured":"Banyu Pharmaceutical, C. O. & Ltd (eds) JANUVIA\u00ae Tablets Report on the Results of Post-marketing Surveillance. (2010). https:\/\/www.msdconnect.jp\/wp-content\/uploads\/sites\/5\/2021\/02\/eppv_midterm2_januvia_tab.pdf"},{"key":"96103_CR11","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.clinthera.2011.09.028","volume":"33","author":"KR Richard","year":"2011","unstructured":"Richard, K. R., Shelburne, J. S. & Kirk, J. K. Tolerability of dipeptidyl peptidase-4 inhibitors: a review. Clin. Ther. 33, 1609\u20131629 (2011).","journal-title":"Clin. Ther."},{"key":"96103_CR12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00535-021-01843-7","volume":"57","author":"H Miwa","year":"2022","unstructured":"Miwa, H. et al. Evidence-based clinical practice guidelines for functional dyspepsia 2021. Journal of gastroenterology. J. Gastroenterol. 57, 47\u201361 (2022).","journal-title":"J. Gastroenterol."},{"key":"96103_CR13","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00535-021-01769-0","volume":"56","author":"T Kamada","year":"2021","unstructured":"Kamada, T. et al. Evidence-based clinical practice guidelines for peptic ulcer disease 2020. J. Gastroenterol. 56, 303\u2013322 (2021).","journal-title":"J. Gastroenterol."},{"key":"96103_CR14","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00535-022-01861-z","volume":"57","author":"K Iwakiri","year":"2022","unstructured":"Iwakiri, K. et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021. J. Gastroenterol. 57, 267\u2013285 (2022).","journal-title":"J. Gastroenterol."},{"key":"96103_CR15","first-page":"1034","volume":"25","author":"P Nunnari","year":"2021","unstructured":"Nunnari, P., Ceccarelli, G., Ladiana, N. & Notaro, P. Prescribing cascades and medications most frequently involved in pain therapy: a review. Eur. Rev. Med. Pharmacol. Sci. 25, 1034\u20131041 (2021).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"96103_CR16","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1136\/bmj.315.7115.1096","volume":"315","author":"PA Rochon","year":"1997","unstructured":"Rochon, P. A. & Gurwitz, J. H. Optimising drug treatment for elderly people: the prescribing cascade. BMJ (Clinical Res. ed). 315, 1096\u20131099 (1997).","journal-title":"BMJ (Clinical Res. ed)"},{"key":"96103_CR17","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1248\/yakushi.23-00068","volume":"143","author":"M Maeda","year":"2023","unstructured":"Maeda, M., Hasegawa, Y., Tsukioka, R. & Oishi, M. [Effect of a family pharmacist system on medication adherence of patients with dyslipidemia during a COVID-19 epidemic]. Yakugaku Zasshi. 143, 765\u2013775 (2023).","journal-title":"Yakugaku Zasshi"},{"key":"96103_CR18","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/00001648-199609000-00005","volume":"7","author":"J Hallas","year":"1996","unstructured":"Hallas, J. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology 7, 478\u2013484 (1996).","journal-title":"Epidemiology"},{"key":"96103_CR19","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/pds.5351","volume":"31","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. Risk of neuropsychiatric adverse events associated with varenicline treatment for smoking cessation among Dutch population: A sequence symmetry analysis. Pharmacoepidemiol. Drug Saf. 31, 158\u2013166 (2022).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"96103_CR20","doi-asserted-by":"crossref","first-page":"e1918425","DOI":"10.1001\/jamanetworkopen.2019.18425","volume":"2","author":"SM Vouri","year":"2019","unstructured":"Vouri, S. M. et al. Magnitude of and characteristics associated with the treatment of calcium channel Blocker-Induced Lower-Extremity edema with loop diuretics. JAMA Netw. Open. 2, e1918425 (2019).","journal-title":"JAMA Netw. Open."},{"key":"96103_CR21","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s10654-017-0281-8","volume":"32","author":"EC Lai","year":"2017","unstructured":"Lai, E. C. et al. Sequence symmetry analysis in pharmacovigilance and pharmacoepidemiologic studies. Eur. J. Epidemiol. 32, 567\u2013582 (2017).","journal-title":"Eur. J. Epidemiol."},{"key":"96103_CR22","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/ajh\/hpac013","volume":"35","author":"SM Vouri","year":"2022","unstructured":"Vouri, S. M. et al. Evaluation of a Beta-Blocker-Edema-Loop diuretic prescribing cascade: A prescription sequence symmetry analysis. Am. J. Hypertens. 35, 601\u2013609 (2022).","journal-title":"Am. J. Hypertens."},{"key":"96103_CR23","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12874-023-02108-y","volume":"24","author":"MRS Hendrix","year":"2024","unstructured":"Hendrix, M. R. S. et al. Prescription sequence symmetry analysis (PSSA) to assess prescribing cascades: a step-by-step guide. BMC Med. Res. Methodol. 24, 8 (2024).","journal-title":"BMC Med. Res. Methodol."},{"key":"96103_CR24","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/pds.3780","volume":"24","author":"N Pratt","year":"2015","unstructured":"Pratt, N. et al. Prescription sequence symmetry analysis: assessing risk, Temporality, and consistency for adverse drug reactions across datasets in five countries. Pharmacoepidemiol. Drug Saf. 24, 858\u2013864 (2015).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"2","key":"96103_CR25","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/jdi.12711","volume":"9","author":"X Gao","year":"2018","unstructured":"Gao, X. et al. Meta-analysis and critical review on the efficacy and safety of alpha-glucosidase inhibitors in Asian and non-Asian populations. J. Diabetes Invest. 9 (2), 321\u2013331 (2018).","journal-title":"J. Diabetes Invest."},{"key":"96103_CR26","doi-asserted-by":"crossref","first-page":"154","DOI":"10.2337\/diacare.28.1.154","volume":"28","author":"FA van de Laar","year":"2005","unstructured":"van de Laar, F. A. et al. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care. 28, 154\u2013163 (2005).","journal-title":"Diabetes Care"},{"key":"96103_CR27","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/00001648-199710000-00009","volume":"8","author":"J Hallas","year":"1997","unstructured":"Hallas, J., Gaist, D. & Bjerrum, L. The waiting time distribution as a graphical approach to epidemiologic measures of drug utilization. Epidemiology 8, 666\u2013670 (1997).","journal-title":"Epidemiology"},{"key":"96103_CR28","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1136\/bmj.296.6632.1313","volume":"296","author":"JA Morris","year":"1988","unstructured":"Morris, J. A. & Gardner, M. J. Calculating confidence intervals for relative risks (odds ratios) and standardised ratios and rates. Br. Med. J. (Clin Res. Ed). 296, 1313\u20131316 (1988).","journal-title":"Br. Med. J. (Clin Res. Ed)"},{"key":"96103_CR29","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/pds.3417","volume":"22","author":"IA Wahab","year":"2013","unstructured":"Wahab, I. A., Pratt, N. L., Wiese, M. D., Kalisch, L. M. & Roughead, E. E. The validity of sequence symmetry analysis (SSA) for adverse drug reaction signal detection. Pharmacoepidemiol. Drug Saf. 22, 496\u2013502 (2013).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"96103_CR30","unstructured":"Council for International Organizations of Medical Sciences (CIOMS). Practical Aspects of Signal Detection in Phamacovigilance (Council for International Organizations of Medical Sciences, 2010)."},{"key":"96103_CR31","doi-asserted-by":"crossref","unstructured":"Hauben, M. & Aronson, J. K. Defining \u2018signal\u2019 and its subtypes in pharmacovigilance based on a systematic review of previous definitions. Drug Saf., 32, 99\u2013110 (2009).","DOI":"10.2165\/00002018-200932020-00003"},{"key":"96103_CR32","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s40360-020-00447-w","volume":"21","author":"J Huang","year":"2020","unstructured":"Huang, J., Jia, Y., Sun, S. & Meng, L. Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system. BMC Pharmacol. Toxicol. 21, 68 (2020).","journal-title":"BMC Pharmacol. Toxicol."},{"key":"96103_CR33","doi-asserted-by":"crossref","first-page":"1364110","DOI":"10.3389\/fphar.2024.1364110","volume":"15","author":"KA Alenzi","year":"2024","unstructured":"Alenzi, K. A., Alsuhaibani, D., Batarfi, B. & Alshammari, T. M. Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database. Front. Pharmacol. 15, 1364110 (2024).","journal-title":"Front. Pharmacol."},{"key":"96103_CR34","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/jdi.12095","volume":"4","author":"K Kanasaki","year":"2013","unstructured":"Kanasaki, K. et al. Three ileus cases associated with the use of dipeptidyl peptidase-4 inhibitors in diabetic patients. J. Diabetes Invest. 4, 673\u2013675 (2013).","journal-title":"J. Diabetes Invest."},{"key":"96103_CR35","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1080\/14740338.2023.2284992","volume":"23","author":"A Muhammed","year":"2024","unstructured":"Muhammed, A., Thomas, C., Kalaiselvan, V. & Undela, K. Risk of pancreatitis and pancreatic carcinoma for anti-diabetic medications: findings from real-world safety data analysis and systematic review and meta-analysis of randomized controlled trials. Exp. Opin. Drug Saf. 23, 731\u2013742 (2024).","journal-title":"Exp. Opin. Drug Saf."},{"key":"96103_CR36","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jama.1967.03130080024006","volume":"201","author":"P Mandelstam","year":"1967","unstructured":"Mandelstam, P. & Lieber, A. Esophageal dysfunction in diabetes neuropathy. Gastroneuropathy. JAMA 201, 582\u2013586 (1967).","journal-title":"JAMA"},{"key":"96103_CR37","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s40471-018-0176-6","volume":"5","author":"N Pratt","year":"2018","unstructured":"Pratt, N. & Roughead, E. Assessment of medication safety using only dispensing data. Curr. Epidemiol. Rep. 5, 357\u2013369 (2018).","journal-title":"Curr. Epidemiol. Rep."},{"key":"96103_CR38","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12874-017-0457-7","volume":"18","author":"Y Takeuchi","year":"2018","unstructured":"Takeuchi, Y., Shinozaki, T. & Matsuyama, Y. A comparison of estimators from self-controlled case series, case-crossover design, and sequence symmetry analysis for pharmacoepidemiological studies. BMC Med. Res. Methodol. 18, 4 (2018).","journal-title":"BMC Med. Res. Methodol."},{"key":"96103_CR39","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/MCG.0b013e3181eeb5e9","volume":"45","author":"JK Jaffe","year":"2011","unstructured":"Jaffe, J. K., Paladugu, S., Gaughan, J. P. & Parkman, H. P. Characteristics of nausea and its effects on quality of life in diabetic and idiopathic gastroparesis. J. Clin. Gastroenterol. 45, 317\u2013321 (2011).","journal-title":"J. Clin. Gastroenterol."},{"key":"96103_CR40","first-page":"840","volume":"82","author":"FE Murray","year":"1987","unstructured":"Murray, F. E. et al. Esophageal function in diabetes mellitus with special reference to acid studies and relationship to peripheral neuropathy. Am. J. Gastroenterol. 82, 840\u2013843 (1987).","journal-title":"Am. J. Gastroenterol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96103-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96103-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96103-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T23:04:08Z","timestamp":1743807848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96103-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["96103"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-96103-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"assertion":[{"value":"23 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ayana Funabashi is an employee of AIN PHARMACIEZ INC. Hitoshi Ito, Mamoru Maeda, Yoshitaka Hasegawa and Ryota Tsukioka are employees of AIN HOLDINGS INC. The other author has no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11494"}}